{"id":"NCT00884273","sponsor":"Ferring Pharmaceuticals","briefTitle":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","officialTitle":"A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-04-20","resultsPosted":"2012-04-11","lastUpdate":"2013-11-13"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":["FE200486","FIRMAGON"]},{"type":"DRUG","name":"Goserelin","otherNames":["ZOLADEX"]},{"type":"DRUG","name":"Bicalutamide","otherNames":["CASODEX"]}],"arms":[{"label":"Degarelix 240 mg/80 mg","type":"EXPERIMENTAL"},{"label":"Goserelin (3.6 mg) + bicalutamide (50 mg)","type":"ACTIVE_COMPARATOR"}],"summary":"This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix (240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in prostate volume.\n\nThe hypothesis was that degarelix could decrease prostate size at least as effectively as the combination of a GnRH agonist with an anti-androgen for flare protection.","primaryOutcome":{"measure":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","timeFrame":"After treatment of 12 weeks compared to Baseline","effectByArm":[{"arm":"Degarelix 240 mg/80 mg","deltaMin":-37.2,"sd":16.8},{"arm":"Goserelin (3.6 mg) + Bicalutamide (50 mg)","deltaMin":-39,"sd":17.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.36"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":46,"countries":["Belgium","Denmark","Finland","Italy","Norway","Portugal","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["22500884","34350976"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":84},"commonTop":["Hot flush","Injection site pain","Hyperhidrosis","Erectile dysfunction","Weight decreased"]}}